A U.S.-based life sciences organization that recently merged with a European-based pharmaceutical company as well as a few smaller tertiary companies with additional assets.
Before the strategic merger, both the European and U.S. client had no prior experience in each other’s respective markets. As they began to operate within their new territories, the executives from both companies were struggling in a variety of different capacities:
The newly merged companies were also struggling with professional and cultural differences, as well as language barriers, as they began to integrate during the middle of the coronavirus pandemic. As a result, the two companies continued to act as two separate entities, rather than one cohesive organization.
To streamline processes and highlight the strengths of both organizations, Baker Tilly professionals evaluated the company’s overall compliance needs. As a result, Baker Tilly helped design a new corporate compliance program that was implemented globally throughout the entire organization.
Through this program, Baker Tilly drafted new policies and procedures that were put into place, as well as trained employees globally on these new practices.
Baker Tilly also coordinated with its affiliate firms (that are a part of the Baker Tilly International global network) to help support the language barrier, translate meetings and deliver a final report in two separate languages.
With the help of Baker Tilly and a new corporate compliance program in place, the organization was able to streamline its policies across the entire enterprise, which enabled executives to feel confident making decisions in a new market. In addition, with the help of Baker Tilly’s global network, the client was also able to easily navigate communications between both entities and come together to create a unified vision that both teams believed in and agreed upon.
For more information on this topic or to learn more about our compliance and ethics solutions for life science companies, connect with us today.